126 related articles for article (PubMed ID: 19577419)
1. Drotrecogin alfa (activated) for severe sepsis: could we consider a shorter treatment period in patients with a favorable course?
Ahishakiye D; Lorent S; De Backer D; Gottignies P; Vincent JL
J Crit Care; 2009 Dec; 24(4):590-4. PubMed ID: 19577419
[TBL] [Abstract][Full Text] [Related]
2. Drotrecogin alfa (activated): diffusion from clinical trials to clinical practice.
Ridley S; Lwin A; Wyncoll D; Lippett S; Watson D; Gunning K; Higgins D
Eur J Anaesthesiol; 2008 Mar; 25(3):211-6. PubMed ID: 18031590
[TBL] [Abstract][Full Text] [Related]
3. Timing of drotrecogin alfa (activated) initiation in treatment of severe sepsis: a database cohort study of hospital mortality, length of stay, and costs.
Ernst FR; Johnston JA; Pulgar S; He J; Ball DE; Young JK; Cooper LM
Curr Med Res Opin; 2007 Jan; 23(1):235-44. PubMed ID: 17207305
[TBL] [Abstract][Full Text] [Related]
4. Predictors of hospital mortality for patients with severe sepsis treated with Drotrecogin alfa (activated).
Micek ST; Isakow W; Shannon W; Kollef MH
Pharmacotherapy; 2005 Jan; 25(1):26-34. PubMed ID: 15767217
[TBL] [Abstract][Full Text] [Related]
5. 90-day follow-up of patients treated with Drotrecogin Alfa (activated) for severe sepsis: a Belgian open label study.
Decruyenaere J; De Backer D; Spapen H; Laterre PF; Raemaekers J; Rogiers P; Trine H; Sartral M; Haentjens T; Wagner T
Acta Clin Belg; 2009; 64(1):16-22. PubMed ID: 19317237
[TBL] [Abstract][Full Text] [Related]
6. Effects of drotrecogin alfa activated on microcirculatory alterations in patients with severe sepsis.
De Backer D; Verdant C; Chierego M; Koch M; Gullo A; Vincent JL
Crit Care Med; 2006 Jul; 34(7):1918-24. PubMed ID: 16715034
[TBL] [Abstract][Full Text] [Related]
7. Results of severe sepsis treatment program using recombinant human activated protein C in Poland.
Kübler A; Mayzner-Zawadzka E; Durek G; Gaszyński W; Karpel E; Mikaszewska-Sokolewicz M; Majak P
Med Sci Monit; 2006 Mar; 12(3):CR107-12. PubMed ID: 16501420
[TBL] [Abstract][Full Text] [Related]
8. Is worsening multiple organ failure the cause of death in patients with severe sepsis?
Vincent JL; Nelson DR; Williams MD
Crit Care Med; 2011 May; 39(5):1050-5. PubMed ID: 21317650
[TBL] [Abstract][Full Text] [Related]
9. Hospital mortality and resource use in subgroups of the Recombinant Human Activated Protein C Worldwide Evaluation in Severe Sepsis (PROWESS) trial.
Laterre PF; Levy H; Clermont G; Ball DE; Garg R; Nelson DR; Dhainaut JF; Angus DC
Crit Care Med; 2004 Nov; 32(11):2207-18. PubMed ID: 15640632
[TBL] [Abstract][Full Text] [Related]
10. Cost effectiveness of drotrecogin alfa (activated) for the treatment of severe sepsis in the United Kingdom.
Davies A; Ridley S; Hutton J; Chinn C; Barber B; Angus DC
Anaesthesia; 2005 Feb; 60(2):155-62. PubMed ID: 15644013
[TBL] [Abstract][Full Text] [Related]
11. The use of drotrecogin alfa (activated) in solid organ transplant patients: a case series.
Berkman S; Weimert NA; Taber DJ; Baillie GM; Lin A; Baliga P; Chavin KD
Transpl Infect Dis; 2009 Jun; 11(3):269-76. PubMed ID: 19392728
[TBL] [Abstract][Full Text] [Related]
12. [Cost-effectiveness of drotrecogin alpha [activated] in the treatment of severe sepsis in Spain].
Sacristán JA; Prieto L; Huete T; Artigas A; Badia X; Chinn C; Hudson P
Gac Sanit; 2004; 18(1):50-7. PubMed ID: 14980173
[TBL] [Abstract][Full Text] [Related]
13. Effects of drotrecogin alfa (activated) on organ dysfunction in the PROWESS trial.
Vincent JL; Angus DC; Artigas A; Kalil A; Basson BR; Jamal HH; Johnson G; Bernard GR;
Crit Care Med; 2003 Mar; 31(3):834-40. PubMed ID: 12626993
[TBL] [Abstract][Full Text] [Related]
14. Drotrecogin alfa (activated): a pharmacoeconomic review of its use in severe sepsis.
Frampton JE; Foster RH
Pharmacoeconomics; 2004; 22(7):445-76. PubMed ID: 15137883
[TBL] [Abstract][Full Text] [Related]
15. Clinical response to unintentionally rapid infusion of drotrecogin alfa (activated).
Urban TM; Mitchell GA; Wellborn-Kim JJ; Terneus WF; Callahan CM; Mendes J; Webber SL
Am J Health Syst Pharm; 2010 Jul; 67(14):1174-7. PubMed ID: 20592322
[TBL] [Abstract][Full Text] [Related]
16. Drotrecogin alfa (activated) in severe sepsis.
Friedrich JO
N Engl J Med; 2006 Jan; 354(1):94-6; author reply 94-6. PubMed ID: 16394311
[No Abstract] [Full Text] [Related]
17. Drotrecogin alfa (activated): is there room for improvement?
Cunningham K; Jankovic Z
Eur J Anaesthesiol; 2008 Nov; 25(11):952. PubMed ID: 18533075
[No Abstract] [Full Text] [Related]
18. Assessing the effect of the Surviving Sepsis Campaign treatment guidelines on clinical outcomes in a community hospital.
Patel GW; Roderman N; Gehring H; Saad J; Bartek W
Ann Pharmacother; 2010 Nov; 44(11):1733-8. PubMed ID: 20978215
[TBL] [Abstract][Full Text] [Related]
19. Extended drotrecogin alfa (activated) treatment in patients with prolonged septic shock.
Dhainaut JF; Antonelli M; Wright P; Desachy A; Reignier J; Lavoue S; Charpentier J; Belger M; Cobas-Meyer M; Maier C; Mignini MA; Janes J
Intensive Care Med; 2009 Jul; 35(7):1187-95. PubMed ID: 19263034
[TBL] [Abstract][Full Text] [Related]
20. Evaluating the use of Drotrecogin alfa (activated) in adult severe sepsis: a Canadian multicenter observational study.
Kanji S; Perreault MM; Chant C; Williamson D; Burry L
Intensive Care Med; 2007 Mar; 33(3):517-23. PubMed ID: 17325837
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
